Hudson joined the Tuveson Lab in July 2023 with his work aiming to develop theranostics for PET imaging and targeted radionuclide therapy for PDAC patients. Before joining CSHL, he completed his Ph.D. in Oncology in the Cornelissen Lab at the University of Oxford (UK), where his research focused on developing PET/SPECT imaging agents for interrogating abnormal p53 expression in cancer. He also holds a MS in Cancer from UCL (UK) and B.Tech Industrial Microbiology and Biotechnology  from Technical University of Mombasa (Kenya).